Articles published by Ocugen
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
April 27, 2023
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
April 26, 2023
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 20, 2023
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
February 17, 2023
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen Appoints Quan A. Vu as Chief Business Officer
February 01, 2023
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
January 31, 2023
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
December 13, 2022
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
December 07, 2022
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
November 28, 2022
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
November 08, 2022
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
October 19, 2022
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
October 12, 2022
From Ocugen
Via GlobeNewswire
Tickers
OCGN
![](https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.